Cationic nanocarriers as potent adjuvants for recombinant S-RBD vaccine of SARS-CoV-2  

作　　者：Hong Lei Aqu Alu Jingyun Yang Cai He Weiqi Hong Zesheng Cheng Li Yang Jiong Li Zhenling Wang Wei Wang Guangwen Lu Xiawei Wei 

机构地区：[1]Laboratory of Aging Research and Cancer Drug Target,State Key Laboratory of Biotherapy and Cancer Center,National Clinical Research Center for Geriatrics,West China Hospital,Sichuan University,610041 Sichuan,Chengdu,China [2]Emergency Department,State Key Laboratory of Biotherapy,West China Hospital,Sichuan University,610041 Sichuan,Chengdu,China

出　　处：《Signal Transduction and Targeted Therapy》2021年第1期8-10,共3页信号转导与靶向治疗（英文）

基　　金：This work was supported by the National Key Research and Development Program of China(No.2016YFA0201402);National Natural Science Foundation Regional Innovation and Development(U19A2003);The National Major Scientific and Technological Special Project for“Significant New Drugs Development”(No.2018ZX09733001).

摘　　要：Dear Editor,The worldwide outbreak of severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)infection has urged the investigation of preventive vaccines.Recently,our team has developed a recombinant protein vaccine,targeting receptor binding domain(RBD)of the spike protein(S-RBD)of SARS-CoV-2,which could induce a potent antibody response and protect non-human primates from SARS-CoV-2 challenge.1 The recombinant RBD protein is proved as a potent antigen and a novel adjuvant is in demand for the effective stimulation of adaptive immunity.

关 键 词：ADJUVANT VACCINE stimulation 

分 类 号：R392-33[医药卫生—免疫学]